## American College of Radiology ACR Appropriateness Criteria®

## **Transgender Breast Cancer Screening**

Variant 1: Breast cancer screening. Transfeminine (male-to-female) patient, 40 years of age or older with past or current hormone use equal to or greater than 5 years. Average-risk patient.

	Appropri	iateness									F	inal	Tabu	ılatio	ns		
Procedure	Categ	gory	SOE	Adults RR	L	Peds RRL	Rating	Median	1	2	3	4	5	6		8	9
Mammography screening	May approp	be oriate	Strong	�� 0.1-1m	ıSv		6	6	0	0	0	1	7	4	5	1	1
	•		References			Study	Quality										
			2 (31088823)				4										
			21 (25994431)				4										
			1 (25428790)				4										
			3 (24010586)				4										
			18 (21266549)				4										
			10 (29392096)				4										
		10 (29392096) 19 (9718051)					2										
			20 (12117397)				2										
Digital breast tomosynthesis screening	May approp	be priate	Strong	�� 0.1-1m	ıSv		6	6	0	0	0	2	7	5	4	0	1
			References			Study	Quality		-								
			2 (31088823)				4										
			21 (25994431)				4										
			1 (25428790)				4										
			3 (24010586)				4										
			18 (21266549)				4										
			10 (29392096)				4										

			19 (9718051)				2										
			20 (12117397)				2										
MRI breast without IV contrast	Usuall approp	y not oriate	Limited	O 0 mSv	/	O 0 mSv [ped]	1	1	15	0	1	1	1	0	0	0	1
			References			Study	Quality										
			17 (29724416)				4										
MRI breast without and with IV contrast	Usuall approp	y not oriate	Limited	O 0 mSv	/	O 0 mSv [ped]	1	1	10	1	2	1	4	0	0	0	1
			References			Study	Quality										
			4 (25415740)				4										
			10 (29392096)				4										
US breast	Usuall approp	y not oriate	Limited	O 0 mSv	/	O 0 mSv [ped]	1	1	12	1	3	1	0	1	0	0	1
			References			Study	Quality			-			-	•	•	•	
			11 (19359116)				3										

Variant 2: Breast cancer screening. Transfeminine (male-to-female) patient, 25 to 30 years of age or older with past or current hormone use equal to or greater than 5 years. Higher-than-average risk (patient with personal history of breast cancer or chest irradiation at 10 to 30 years of age, patient with genetic predisposition to breast cancer, patient with family history of breast or ovarian cancer, and untested patient with first-degree relative with genetic predisposition to breast cancer).

n 1	Appropriateness	COF	A L L DDY	n i nni	ъ.	3.6.11			F	inal '	Гаbи	latio	ns		
Procedure	Category	SOE	Adults RRL	Peds RRL	Rating	Median	1	2	3	4	5	6	7	8	9
Mammography screening	Usually appropriate	Strong	<b>⊕⊕</b> 0.1-1mSv		7	7	0	0	0	0	1	1	13	1	3

References	Study Quality
25 (29101979)	4
2 (31088823)	4
1 (25428790)	4
24 (25042481)	4
3 (24010586)	4
18 (21266549)	4

	_															
		10 (29392096)				4										
		19 (9718051)				2										
		20 (12117397)				2										
		22 (31526252)				3										
Digital breast tomosynthesis screening	Usual appropr	Strong	�� 0.1-1m\$	Sv		7	7	0	0	0	0	1	3	12	0	3
		References			Study	Quality										
		25 (29101979)				4										
		2 (31088823)				4										
		1 (25428790)				4										
		24 (25042481)				4										
		3 (24010586)				4										
		18 (21266549)				4										
		19 (9718051)				2										
		20 (12117397)				2										
		22 (31526252)				3			1	1						
MRI breast without and with IV contrast	Usually appropr	Limited	O 0 mSv		O 0 mSv [ped]	3	3	4	3	8	1	1	1	1	0	0
		References			Study	Quality										
		4 (25415740)				4										
		10 (29392096)				4										
MRI breast without IV contrast	Usually appropr	Limited	O 0 mSv		O 0 mSv [ped]	1	1	17	2	0	0	0	0	0	0	0
		References			Study	Quality										
		17 (29724416)				4										
US breast	Usually appropr	Expert Consensus	O 0 mSv		O 0 mSv [ped]	1	1	16	3	0	0	0	0	0	0	0

Variant 3: Breast cancer screening. Transfeminine (male-to-female) patient with no hormone use (or hormone use less than 5 years) at any age. Average-risk patient.

n 1	Appropri	ateness	COF	4 1 14 DD	, D 1 DDY	D (1	3.5 11			F	'inal '	Tabu	latio	ns		
Procedure	Categ		SOE	Adults RRI	L Peds RRL	Rating	Median	1	2	3	4	5	6	7	8	9
Mammography screening	Usuall approp		Limited	�� 0.1-1m\$	Sv	1	1	14	2	1	0	0	0	0	0	2
			References		Stud	y Quality										
			1 (25428790)			4										
			26 (22393212)			4										
MRI breast without IV contrast	Usuall approp		Limited	O 0 mSv	O 0 mSv [ped]	1	1	14	2	1	1	0	0	0	0	1
			References		Stud	y Quality										
			17 (29724416)			4										
MRI breast without and with IV contrast	Usuall approp		Expert Consensus	O 0 mSv	O 0 mSv [ped]	1	1	15	2	1	0	0	0	0	0	1
US breast	Usuall approp		Expert Consensus	O 0 mSv	O 0 mSv [ped]	1	1	14	3	0	0	0	1	0	0	1
Digital breast tomosynthesis screening	Usuall approp		Limited	�� 0.1-1m\$	Sv	1	1	14	2	1	0	0	0	0	0	2
			References		Stud	y Quality										
			1 (25428790)			4										
			26 (22393212)			4										

Variant 4: Breast cancer screening. Transfeminine (male-to-female) patient, 25 to 30 years of age or older with no hormone use (or hormone use less than 5 years). Higher-than-average risk (patient with personal history of breast cancer or chest irradiation at 10 to 30 years of age, patient with genetic predisposition to breast cancer, patient with family history of breast or ovarian cancer, and untested patient with first-degree relative with genetic predisposition to breast cancer).

	Appropri	iateness	COF	4.1.4. DD	\ <b>T</b>	D I DDI	D (1	3.6.11			F	inal '	Гаbu	latio	ns		
Procedure	Categ		SOE	Adults RR	<b>K</b> L	Peds RRL	Rating	Median	1	2	3	4	5	6	7	8	9
Mammography screening	May approp		Limited	�� 0.1-1mSv			5	5	0	1	0	1	11	3	3	0	0
			References			Study	Quality										

			21 (25994431)				4										
			22 (31526252)				3										
			23 (31280425)				3										
Digital breast tomosynthesis screening	May approp	be oriate	Limited	�� 0.1-1m	ıSv		5	5	0	1	0	1	12	2	3	0	0
			References			Study	Quality										
			21 (25994431)				4										
			22 (31526252)				3										
			23 (31280425)				3										
MRI breast without and with IV contrast	Usually approp		Limited	O 0 mSv	′	O 0 mSv [ped]	2	2	5	8	1	1	3	0	1	0	0
			References			Study	Quality										
			4 (25415740)				4										
			17 (29724416)				4										
			10 (29392096)				4										
MRI breast without IV contrast	Usually approp		Limited	O 0 mSv	′	O 0 mSv [ped]	1	1	18	0	1	0	0	0	0	0	0
			References			Study	Quality										
			17 (29724416)			_	4										
US breast	Usually approp	y not oriate	Expert Consensus	O 0 mSv	,	O 0 mSv [ped]	1	1	17	1	0	0	1	0	0	0	0

Variant 5: Breast cancer screening. Transmasculine (female-to-male) patient with bilateral mastectomies ("top surgery") at any age and any risk.

D 1	Appropriateness	COF	A L L DDI	n i nnr	D. (*	3.6 11			F	inal '	Гаbи	latio	ns		
Procedure	Category	SOE	Adults RRL	Peds RRL	Rating	Median	1	2	3	4	5	6	7	8	9
Mammography screening	Usually not appropriate	Expert Consensus	�� 0.1-1mSv		1	1	15	2	1	0	0	0	0	0	1
MRI breast without IV contrast	Usually not appropriate	Expert Consensus	O 0 mSv	O 0 mSv [ped]	1	1	16	1	1	0	0	0	0	0	1

MRI breast without and with IV contrast	Usually approp	Expert Consensus	O 0 mSv	/	O 0 mSv [ped]	1	1	16	0	1	1	0	0	0	0	1
US breast	Usually approp	Limited	O 0 mSv	/	O 0 mSv [ped]	1	1	16	0	0	0	1	1	0	0	1
		References			Study	Quality										
		28 (-3173791)				4										
Digital breast tomosynthesis screening	Usually approp	Expert Consensus	�� 0.1-1m	nSv		1	1	15	2	1	0	0	0	0	0	1

Variant 6: Breast cancer screening. Transmasculine (female-to-male) patient with reduction mammoplasty or no chest surgery, 40 years of age or older. Average-risk patient (less than 15% lifetime risk of breast cancer).

D 1	Appropri	iateness	GOT.	4 1 1/ DD	_	n i nnr	D (1	3.6.11			F	inal '	Tabu	latio	ns		
Procedure	Categ		SOE	Adults RR	L	Peds RRL	Rating	Median	1	2	3	4	5	6	7	8	9
Mammography screening	Usua approp		Limited	�� 0.1-1m	Sv		9	9	1	0	0	0	0	0	1	5	12
			References			Study	Quality										
			25 (29101979)				4		_			_					
Digital breast tomosynthesis screening	Usua approp		Limited	�� 0.1-1m	Sv		9	9	0	1	0	0	0	1	2	3	12
			References			Study	Quality		•								
			25 (29101979)				4										
US breast	Usuall approp		Limited	O 0 mSv	r	O 0 mSv [ped]	2	2	8	2	0	3	6	0	0	0	0
			References			Study	Quality										
			31 (20129267)				4										
			30 (25763719)				4										
			32 (25329763)				3										
			33 (23980217)				3										
			34 (23116728)				2										

		29 (23750571) 25 (29101979)				4										
MRI breast without IV contrast	Usually approp	Expert Consensus	O 0 mSv	,	O 0 mSv [ped]	1	1	14	2	1	1	0	0	0	0	1
MRI breast without and with IV contrast	Usually approp	Expert Consensus	O 0 mSv	,	O 0 mSv [ped]	1	1	12	1	3	1	1	0	0	0	1

Variant 7: Breast cancer screening. Transmasculine (female-to-male) patient with reduction mammoplasty or no chest surgery, 30 years of age or older. Intermediate risk (patient with personal history of breast cancer, lobular neoplasia, atypical ductal hyperplasia, or 15% to 20% lifetime risk of breast cancer).

ъ	Appropriatenes	SS GOT	A L L DDI	D I DDI	D 41	3.6.19	Final Tabulations											
Procedure	Category	SOE	Adults RRL	Peds RRL	Rating	Median	1	2	3	4	5	6	7	8	9			
Mammography screening	Usually appropriate	Limited	�� 0.1-1mS	Sv	9	9	1	0	0	0	0	0	1	6	11			
		References		Study	Quality													
		35 (28648873)			4													
		25 (29101979)				_												
Digital breast tomosynthesis screening	Usually appropriate	Limited	<b>⊕⊕</b> 0.1-1mS	Sv	9	9	0	1	0	0	0	1	2	5	10			
		References		Study														
		35 (28648873)																
		25 (29101979)																
MRI breast without and with IV contrast	May be appropriate	Limited	O 0 mSv	O 0 mSv [ped]	5	5	0	1	0	1	12	3	1	1	0			
		References		Study														
		38 (20651211)																
		37 (21900617)			4													
		36 (21900618)																
		39 (26744477)																
		25 (29101979)			4													

US breast	May approp	_	Strong	O 0 mSv	,	O 0 mSv [ped]	5	5	0	0	1	2	13	2	1	0	0
		References				Study											
		40 (18477782)															
			41 (22474203)														
			25 (29101979)			4											
MRI breast without IV contrast	Usually approp		Expert Consensus	O 0 mSv	,	O 0 mSv [ped]	1	1	15	1	1	0	1	0	0	0	1

Variant 8: Breast cancer screening. Transmasculine (female-to-male) patient with reduction mammoplasty or no chest surgery, 25 to 30 years of age or older. High risk (patient with genetic predisposition to breast cancer, patient with a history of chest irradiation between 10 to 30 years of age, patient with 20% or greater lifetime risk of breast cancer).

D 1	Appropri	oriateness SOE Adults RR		<u>.                                      </u>	Peds RRL	L Rating	37.11	Final Tabulations												
Procedure	Catego			Adults RR	Adults KKL		Median	1	2	3	4	5	6	7	8	9				
Mammography screening	Usua approp		Limited	�� 0.1-1m	Sv		9	9	1	0	1	0	0	0	2	4	11			
		References				Study														
			35 (28648873)		4															
		42 (17392385)			4															
			25 (29101979)				4													
Digital breast tomosynthesis screening	Usua approp		Limited	�� 0.1-1m	Sv		9	9	1	0	1	0	0	1	2	4	10			
			References		Study Quality															
			35 (28648873)		4															
			42 (17392385)		4															
		25 (29101979)			4															
MRI breast without and with IV contrast	Usua approp		Strong	O 0 mSv		O 0 mSv [ped]	8	8	1	0	0	0	0	1	2	7	8			
		·	References		Study Quality															
			49 (17244718)				2													

		43 (17317184)													
		44 (16615112)	ı												
		46 (16293877)													
		47 (15910949)		2											
		48 (24789418)													
		45 (20177029)													
		50 (19884532)													
		25 (29101979)													
US breast	May be appropriate	Strong	O 0 mSv	O 0 mSv [ped]	5	5	1	0	0	2	11	2	1	1	1
		References		Study				•							
		40 (18477782)													
		41 (22474203)	ı												
		25 (29101979)													
MRI breast without IV contrast	Usually not appropriate	Expert Consensus	O 0 mSv	O 0 mSv [ped]	1	1	15	1	1	0	1	0	0	0	1

## **Appendix Key**

A more complete discussion of the items presented below can be found by accessing the supporting documents at the designated hyperlinks.

**Appropriateness Category**: The panel's recommendation for a procedure based on the assessment of the risks and benefits of performing the procedure for the specified clinical scenario.

**SOE**: Strength of Evidence. The assessment of the amount and quality of evidence found in the peer reviewed medical literature for an appropriateness recommendation.

- **References:** The citation number and PMID for the reference(s) associated with the recommendation.
- Study Quality: The assessment of the quality of an individual reference based on the number of study quality elements described in the reference.

RRL: Relative Radiation Level. A population based assessment of the amount of radiation a typical patient may be exposed to during the specified procedure.

Rating: The final rating (1-9 scale) for the procedure as determined by the panel during rating rounds.

Median: The median rating (1-9 scale) for the procedure as determined by the panel during rating rounds.

Final tabulations: A histogram showing the number of panel members who rated the procedure as noted in the column heading (ie, 1, 2, 3, etc.).

Additional supporting documents about the AC methodology and processes can be found at www.acr.org/ac.